Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+3.70%
+5.56%
-1.14%
+6.75%
-0.56%
LLY
Eli Lilly and Company
$766.89
Chart
$747.12 (+2.65%)
$839.96 (-8.70%)
$912.76 (-15.98%)
$807.79 (-5.06%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+3.70%
+5.56%
-1.14%
+6.75%
-0.56%
LLY
Eli Lilly and Company
Current Price
$766.89
Buy
Login to view Eli Lilly and Company (LLY) recommendation from the last 90 days from financial news and social media.
Chart
$747.12 (+2.65%)
$839.96 (-8.70%)
$912.76 (-15.98%)
$807.79 (-5.06%)
LLY Latest Analysis
Dementia Associated with Alzheimers Disease Drug Development Surges with 180 Companies Pushing New Therapeutic Frontiers | DelveInsight. Dementia Associated with Alzheimer'.s Disease Drug Development Surges with 180 Companies Pushing New Therapeutic Frontiers |. DelveInsightDementia associated with Alzheimer'.s disease is a progressive neurodegenerative condition characterized by memory loss cognitive decline and impaired daily functioning. The growing aging population worldwide is l
Thu Jul 17, 2025
Obstructive Sleep Apnea Clinical Trial Pipeline Expands as 12 Companies Driving Innovation in OSA Therapeutics | DelveInsight. Obstructive Sleep Apnea Clinical Trial Pipeline Expands as 12 Companies Driving Innovation in OSA Therapeutics |. DelveInsightThe obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sleep apnea testing (HSAT) AI-powered applications and smart wearables are transforming the diag
Wed Jul 16, 2025
How Do Investors Really Feel About Eli Lilly?. ) short percent of float has fallen 3.96% since its last report. The company recently reported that it has Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if the price ...
Tue Jul 15, 2025
Eli Lilly: Still Too Pricey To Buy.
Tue Jul 15, 2025
Eli Lillys Omvoh wins Health Canada approval for Crohns disease.
Tue Jul 15, 2025
Top Research Reports for Eli Lilly Netflix & GE Aerospace. LLY NFLX and GE lead todays top stock picks with strong growth drivers but face headwinds from pricing rivals and costs.
Mon Jul 14, 2025
Market Whales and Their Recent Bets on LLY Options. Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:) and it'.s something market players shouldn'.t ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown but such a substantial move in LLY usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga'.s optio
Fri Jul 11, 2025
A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts. In the latest quarter 7 analysts provided ratings for Eli Lilly (NYSE:) showcasing a mix of ish and bearish perspectives.The table below summarizes their recent ratings showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.4201010000110000000021010Analysts'. evaluations of 12-month price targets offer additional insights showcasing an average target of $952.29 with a high estima
Fri Jul 11, 2025
This Is What Whales Are Betting On Eli Lilly. Deep-pocketed investors have adopted a ish approach towards Eli Lilly (NYSE:) and it'.s something market players shouldn'.t ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown but such a substantial move in LLY usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga'.s options scanner
Thu Jul 10, 2025
Zepbound Powers Eli Lillys Upbeat Q2 Outlook. ) is set to release its second-quarter earnings on August 7. According to dataanalysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.Expectations are slightly higher for the quarter primarily driven by the strong performance of its obesity drug Zepbound. The pharmaceutical giant a dominant player in the incretin/GLP-1 drug market for obesity and diabetes continues to draw investor attention with its robust pipeline
Wed Jul 9, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings